SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure

DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.

Subsidie
€ 1.998.775
2022

Projectdetails

Introduction

The objective of DISSECT-HF is to generate engineered heart tissue (EHT) with the use of human induced pluripotent stem cells (hiPSC) from specific forms of heart failure (HF). It focuses on three etiologies of HF with a clear trigger and a large inter-individual susceptibility: pregnancy-induced HF, anthracycline cardiotoxicity, and PLN cardiomyopathy. The aim is to unravel common pathophysiological mechanisms involved in the development of HF.

Rationale

The rationale for this project includes:

  • Better understanding of molecular pathways leading to HF and knowledge about inter-individual susceptibility is needed to improve treatment.
  • For detection of changes on a molecular level, cardiac tissue is needed.
  • Using innovative experimental approaches, such as dynamic loaded EHT (dyn-EHT), patient-specific cells, unbiased target finding, and deep phenotyping, I will dissect common disease pathways in the development of HF.

Specific Objectives

The specific objectives of the project are:

  1. Construction of dyn-EHT from patient-specific hiPSC-derived cardiomyocytes, endothelial cells, and fibroblasts.
  2. Generation and deep-phenotyping of dyn-EHT from: A) Females with pregnancy-induced HF (susceptible) and siblings with a normal pregnancy (resilience). B) Cancer patients with severe HF after anthracyclines (susceptibility) and patients who could resist high-dose anthracyclines (resilience). C) Patients with an early PLN cardiomyopathy phenotype (susceptible) versus elderly asymptomatic PLN mutation carriers (resilience).
  3. Identify overlapping and diverse factors.
  4. Validate discoveries and apply in unique human cohorts with data on incident HF.

Workpackages

The workpackages for this project include:

  • WP1: Optimize construction of dyn-EHT from patient-specific hiPSC.
  • WP2: Phenotyping of dyn-EHT from the three HF etiologies focusing on susceptibility and resilience.
  • WP3: Explore the transcriptome and proteome and apply a systems biology approach.
  • WP4: Validate results and explore human relevance in a large cohort with unique phenotyping.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.998.775
Totale projectbegroting€ 1.998.775

Tijdlijn

Startdatum1-11-2022
Einddatum31-10-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • ACADEMISCH ZIEKENHUIS GRONINGENpenvoerder

Land(en)

Netherlands

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

ERC Advanced...€ 2.500.000
2023
Details

Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs

G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.

ERC Starting...€ 1.497.351
2022
Details

DeCiphering Systemic Diurnal MetabOlism and EnDocrinE Signaling in HEART Failure

CODE-HEART aims to uncover how heart failure alters systemic metabolic rhythms through interorgan communication, enhancing understanding of its complex multiorgan nature.

ERC Starting...€ 1.721.063
2025
Details

Programming the EPIcardium to CURE broken hearts

EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.

ERC Advanced...€ 2.499.999
2024
Details

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease

The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.

ERC Starting...€ 1.496.395
2022
Details
ERC Advanced...

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

ERC Advanced Grant
€ 2.500.000
2023
Details
ERC Starting...

Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs

G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.

ERC Starting Grant
€ 1.497.351
2022
Details
ERC Starting...

DeCiphering Systemic Diurnal MetabOlism and EnDocrinE Signaling in HEART Failure

CODE-HEART aims to uncover how heart failure alters systemic metabolic rhythms through interorgan communication, enhancing understanding of its complex multiorgan nature.

ERC Starting Grant
€ 1.721.063
2025
Details
ERC Advanced...

Programming the EPIcardium to CURE broken hearts

EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.

ERC Advanced Grant
€ 2.499.999
2024
Details
ERC Starting...

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease

The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.

ERC Starting Grant
€ 1.496.395
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition€ 1.457.500
2023
Details

Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.

The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.

EIC Pathfinder€ 4.137.668
2023
Details

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder€ 4.475.946
2022
Details

Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients

Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.

EIC Accelerator€ 2.500.000
2022
Details
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition
€ 1.457.500
2023
Details
EIC Pathfinder

Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.

The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.

EIC Pathfinder
€ 4.137.668
2023
Details
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder
€ 4.475.946
2022
Details
EIC Accelerator

Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients

Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.

EIC Accelerator
€ 2.500.000
2022
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.